Retinal Vein Occlusion Pipeline Insight
DelveInsight’s, “Retinal Vein Occlusion - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Retinal Vein Occlusion Understanding
Retinal Vein Occlusion: Overview
Retinal Vein Occlusions occur when there is a blockage of veins carrying blood with needed oxygen and nutrients away from the nerve cells in the retina. A blockage in the retina’s main vein is referred to as a central Retinal Vein Occlusion (CRVO), while a blockage in a smaller vein is called a branch Retinal Vein Occlusion (BRVO). Most BRVOs occur at an arteriovenous crossing—an intersection between a retinal artery and vein. These vessels share a common sheath (connective tissue), so when the artery loses flexibility, as with atherosclerosis (hardening of the arteries), the vein is compressed. BRVO causes a sudden, painless loss of vision. If the affected area is not in the center of the eye, BRVO can go unnoticed with no symptoms.
"Retinal Vein Occlusion - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinal Vein Occlusion pipeline landscape is provided which includes the disease overview and Retinal Vein Occlusion treatment guidelines. The assessment part of the report embraces, in depth Retinal Vein Occlusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinal Vein Occlusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Retinal Vein Occlusion R&D. The therapies under development are focused on novel approaches to treat/improve Retinal Vein Occlusion.
Retinal Vein Occlusion Emerging Drugs Chapters
This segment of the Retinal Vein Occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Retinal Vein Occlusion Emerging Drugs
Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, it is in Phase III stage of development to treat Retinal Vein Occlusion (RVO).
KSI-301: Kodiak Sciences
KSI-301 is currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed towards a once every two months or longer treatment regimen.
Further product details are provided in the report……..
Retinal Vein Occlusion: Therapeutic Assessment
This segment of the report provides insights about the different Retinal Vein Occlusion drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Retinal Vein Occlusion
There are approx. 15+ key companies which are developing the therapies for Retinal Vein Occlusion. The companies which have their Retinal Vein Occlusion drug candidates in the most advanced stage, i.e. phase III include, Novartis.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Retinal Vein Occlusion: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Retinal Vein Occlusion therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinal Vein Occlusion drugs.
Retinal Vein Occlusion Report Insights
- Retinal Vein Occlusion Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Retinal Vein Occlusion Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Retinal Vein Occlusion drugs?
- How many Retinal Vein Occlusion drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinal Vein Occlusion?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinal Vein Occlusion therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Retinal Vein Occlusion and their status?
- What are the key designations that have been granted to the emerging drugs?